Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Monalizumab: inhibiting the novel immune checkpoint NKG2A

Fig. 1

Schematic model describing the effects of HLA-E expression in the tumor microenvironment (TME) and the use of monalizumab to abrogate inhibition of NKG2A-expressing cells. a HLA-E expression on tumors mediates inhibition of NKG2A-expressing NK cells and CD8+ T cells and leads to tumor escape. b Use of NKG2A-blocking antibody monalizumab unleashes inhibition of NKG2A-expressing cells and promotes activation of NK cells and CD8+ T cells

Back to article page